Contravisory Investment Management’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Contravisory Investment Management’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-366	Closed	-$15K	–	339
2019 Q1	$15K	Sell	366 -18	-5%	-$732	0.01%	255
2018 Q4	$14K	Buy	384 +193	+101%	+$8.24K	0.01%	243
2018 Q3	$9K	Buy	+191	New	+$9.05K	﹤0.01%	242
2014 Q4	–	Sell	-500	Closed	-$27K	–	177
2014 Q3	$27K	Hold	500	–	–	0.01%	93
2014 Q2	$26K	Buy	+500	New	+$24.1K	0.01%	96

Other funds holding XPH

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

HCIA

Hochman Cole Investment Advisors Deerfield, Illinois $255M AUM 23.27% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Contravisory Investment Management's XPH Position: Q2 2019 in Review

Contravisory Investment Management sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q2 2019, closing a stake of 366 shares — an estimated $15K sold.

Contravisory Investment Management first reported a position in XPH in Q2 2014 and held it in 5 quarters. The position peaked at $27K in Q3 2014. 61 funds tracked by Wall St. Rank hold XPH as of Q2 2019.

Contravisory Investment Management reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q2 2019 after selling out during the quarter.
Contravisory Investment Management sold 366 State Street SPDR S&P Pharmaceuticals ETF shares in Q2 2019, an estimated $15K.
Contravisory Investment Management first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q2 2014 and held it in 5 quarters.
Contravisory Investment Management's State Street SPDR S&P Pharmaceuticals ETF position peaked at $27K in Q3 2014.
61 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q2 2019.

Based on Contravisory Investment Management's 13F filing for Q2 2019, filed 9 Jul 2019.